Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone425-205-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.62 million
Profitability
Miscellaneous
Employees202
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' Earnings History.
When is Alder Biopharmaceuticals' next earnings date?
What price target have analysts set for ALDR?
12 brokerages have issued 12-month target prices for Alder Biopharmaceuticals' stock. Their predictions range from $14.00 to $30.00. On average, they expect Alder Biopharmaceuticals' share price to reach $21.2727 in the next twelve months. This suggests a possible upside of 70.2% from the stock's current price. View Analyst Price Targets for Alder Biopharmaceuticals.
What is the consensus analysts' recommendation for Alder Biopharmaceuticals?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alder Biopharmaceuticals.
What are Wall Street analysts saying about Alder Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $14 PT on ALDR. Alder reported 4Q18 earnings, including cash and STI of $412M. With the filing of eptinezumab’s BLA last week, the company expects to launch the drug by early next year, and we believe it is in good position to fund building out a “right-sized” neurology/headache-specialist focused sales force, as well as other launch prep this year, for a cash runway into 2020. We continue to believe that epti’ has perhaps the best and differentiated clinical profile and dosing paradigm, at least for the most-highly burdened chronic or fEM patient." (2/26/2019)
- 2. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (2/18/2019)
- 3. Mizuho analysts commented, "We applied a weighted average valuation methodology to Alder using DCF and EV/Sales under assumptions of commercialization of Eptinezumab (ALD 403) US sales in 2Q 2020 and EU royalties in 2020. Our estimated 2028 FCF is $495 million and terminal value is 4.5x of 2028 estimated FCF. We layered a probability of clinical success of 90% in addition to a 17% discount rate to arrive at our $11 PT using DCF. For EV/Sales, we apply a 3.5 multiple (based on comps) to discounted 2024 sales to derive our $19 PT. Our weighted average valuation is $15 per share. Our base case scenario valuation assumes unadjusted peak sales of $1.1 bn for Eptinezumab in the U.S. in 2025. Our bull case scenario valuation assumes better than anticipated uptake of Eptinezumab with unadjusted peak sales of $1.3 bn in the U.S. in 2025 and a 4.0x terminal multiple, resulting in a $22 PT." (12/12/2018)
Has Alder Biopharmaceuticals been receiving favorable news coverage?
Media headlines about ALDR stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Insmed (INSM), Arena Pharmaceuticals (ARNA) and Portola Pharmaceuticals (PTLA).
What other stocks do shareholders of Alder Biopharmaceuticals own?
Who are Alder Biopharmaceuticals' key executives?
Alder Biopharmaceuticals' management team includes the folowing people:
- Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
- Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
- Ms. Elisabeth A. Sandoval M.B.A., M.B.A, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 57)
- Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
- Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
Who are Alder Biopharmaceuticals' major shareholders?
Alder Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.05%) and Empire Life Investments Inc. (0.01%). Company insiders that own Alder Biopharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.
Which major investors are buying Alder Biopharmaceuticals stock?
How do I buy shares of Alder Biopharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $12.50.
How big of a company is Alder Biopharmaceuticals?
Alder Biopharmaceuticals has a market capitalization of $856.25 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe.
What is Alder Biopharmaceuticals' official website?
How can I contact Alder Biopharmaceuticals?
Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
